How to mitigate risk during ADC development with multi-parameter stability characterization

October 24, 2023

There are unique concerns about the developability properties of antibody-drug conjugates (ADCs) due to the conjugation process.

With multi-parameter assessment of CQAs, it is possible to examine multiple aspects of ADC stability in parallel, to ensure the final product has the greatest chance at clinical success, while saving time and sample early in development.

In this webinar, Product Manager Rebecca Hood dives into the practical considerations of ADC development and characterization.

You’ll learn:

  • What formulation considerations are critical during ADC development
  • How to use high-resolution stability data to compare your ADCs to unconjugated antibodies
  • Which characteristics are impacted by the conjugation process, and how they influence your selection and development process

Check out further video resources from this webinar:

Previous Article
De-risk your ADC development process with these stability considerations
De-risk your ADC development process with these stability considerations

Antibody-drug conjugates, or ADCs, are revolutionary therapeutics that represent a growing proportion of th...

Up next
Explore Prometheus Panta – Biologics developability assessment with four integrated technologies
Explore Prometheus Panta – Biologics developability assessment with four integrated technologies

Developability assessment is a critical part of the evaluation and selection of candidates for further opti...

Ready to tackle your challenging stability characterizations?

Discover tools